Ting Wang

5.1k total citations · 1 hit paper
187 papers, 3.4k citations indexed

About

Ting Wang is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Ting Wang has authored 187 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Molecular Biology, 48 papers in Cancer Research and 43 papers in Oncology. Recurrent topics in Ting Wang's work include Circular RNAs in diseases (27 papers), MicroRNA in disease regulation (26 papers) and Cancer Immunotherapy and Biomarkers (25 papers). Ting Wang is often cited by papers focused on Circular RNAs in diseases (27 papers), MicroRNA in disease regulation (26 papers) and Cancer Immunotherapy and Biomarkers (25 papers). Ting Wang collaborates with scholars based in China, United States and Germany. Ting Wang's co-authors include Fangyi Long, Hong Lin, Rebecca C. Wade, J.Y. Youn, Hua Cai, Umamaheswar Duvvuri, Robert Lafyatis, Cornelius Kürten, Tracy Tabib and Anthony R. Cillo and has published in prestigious journals such as Journal of Biological Chemistry, Neuron and SHILAP Revista de lepidopterología.

In The Last Decade

Ting Wang

174 papers receiving 3.3k citations

Hit Papers

Immune Landscape of Viral- and Carcinogen-Driven Head and... 2020 2026 2022 2024 2020 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ting Wang China 30 1.9k 977 829 536 496 187 3.4k
Yang Gao China 34 2.2k 1.2× 714 0.7× 854 1.0× 349 0.7× 428 0.9× 148 3.5k
Tao Luo China 31 1.9k 1.0× 845 0.9× 666 0.8× 542 1.0× 563 1.1× 124 4.3k
Zakaria Y. Abd Elmageed United States 31 1.6k 0.8× 824 0.8× 583 0.7× 324 0.6× 335 0.7× 94 2.9k
Yan Gong China 33 1.8k 0.9× 639 0.7× 627 0.8× 504 0.9× 654 1.3× 160 3.3k
Emanuela Felley‐Bosco Switzerland 31 1.7k 0.9× 823 0.8× 708 0.9× 445 0.8× 835 1.7× 98 3.7k
Dianzheng Zhang United States 32 2.6k 1.4× 900 0.9× 795 1.0× 460 0.9× 448 0.9× 95 3.8k
Miao He China 37 2.1k 1.1× 1.3k 1.3× 904 1.1× 339 0.6× 439 0.9× 117 3.4k
Zhuo Zhang China 30 1.9k 1.0× 785 0.8× 1.6k 1.9× 305 0.6× 534 1.1× 99 3.5k
Huakan Zhao China 17 1.5k 0.8× 633 0.6× 661 0.8× 785 1.5× 348 0.7× 38 3.2k
Hongmei Li China 35 2.6k 1.4× 937 1.0× 841 1.0× 751 1.4× 383 0.8× 165 4.7k

Countries citing papers authored by Ting Wang

Since Specialization
Citations

This map shows the geographic impact of Ting Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ting Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ting Wang more than expected).

Fields of papers citing papers by Ting Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ting Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ting Wang. The network helps show where Ting Wang may publish in the future.

Co-authorship network of co-authors of Ting Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Ting Wang. A scholar is included among the top collaborators of Ting Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ting Wang. Ting Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xiao, Xiao, et al.. (2025). Kaempferol targets Src to exert its chemopreventive effects on mammary tumorigenesis via regulation of the PI3K/AKT pathway. Phytomedicine. 141. 156701–156701. 1 indexed citations
2.
Du, Meng, Ting Wang, Jinghui Fang, et al.. (2025). Thermal-responsive ultrasound activatable in situ production of therapeutics for real-time imaging and targeted tumor therapy. Theranostics. 15(9). 4212–4228. 2 indexed citations
3.
Luo, Jiawei, et al.. (2024). The PB1 protein of H9N2 influenza A virus inhibits antiviral innate immunity by targeting MAVS for TRIM25-mediated autophagic degradation. Poultry Science. 104(1). 104639–104639. 1 indexed citations
4.
Liu, Yuxuan, Zhimin Li, Ting Wang, et al.. (2024). Concurrent immune checkpoint blockade for enhanced cancer immunotherapy utilizing engineered hybrid nanovesicles. Frontiers in Pharmacology. 15. 1487940–1487940. 3 indexed citations
5.
Liu, Mingyang, Hu Wu, Boshu Ouyang, et al.. (2024). Augmenting Tumor Lysis and Immune Response through HIFU-armed Oncolytic Virus Delivery System. Nano Today. 61. 102571–102571. 2 indexed citations
6.
Wang, Ting, et al.. (2024). Characterizing interactions of endoplasmic reticulum resident proteins in situ through the YST‐PPI method. Biotechnology Journal. 19(8). e2400346–e2400346. 2 indexed citations
7.
Li, Qian, Di Wu, Yu Song, et al.. (2024). In vivo mechanism of the interaction between trimethylamine lyase expression and glycolytic pathways. Food & Function. 16(1). 87–101. 1 indexed citations
8.
Yuan, Lingling, et al.. (2024). Expression Profiles and Bioinformatic Analysis of Circular RNAs in Db/Db Mice with Cardiac Fibrosis. Diabetes Metabolic Syndrome and Obesity. Volume 17. 2107–2120. 3 indexed citations
10.
Zhu, Yongxia, Lidan Zhang, Xuejiao Song, et al.. (2023). Pharmacological inhibition of EZH2 by ZLD1039 suppresses tumor growth and pulmonary metastasis in melanoma cells in vitro and in vivo. Biochemical Pharmacology. 210. 115493–115493. 3 indexed citations
12.
Wang, Ting, et al.. (2023). Immunoglobulin superfamily 6 is a molecule involved in the anti-tumor activity of macrophages in lung adenocarcinoma. BMC Cancer. 23(1). 1170–1170. 2 indexed citations
13.
Wang, Ting, et al.. (2023). Association of variants in GJA8 with familial acorea-microphthalmia-cataract syndrome. European Journal of Human Genetics. 32(4). 413–420. 3 indexed citations
14.
Liu, Rui, Jiyu Miao, Guangyao Kong, et al.. (2023). N6-methyladenosine reader YTHDF2 promotes multiple myeloma cell proliferation through EGR1/p21cip1/waf1/CDK2-Cyclin E1 axis-mediated cell cycle transition. Oncogene. 42(20). 1607–1619. 17 indexed citations
15.
Yang, Xue‐Qiong, et al.. (2022). A new butenolide with antifungal activity from solid co-cultivation of Irpex lacteus and Nigrospora oryzae. Natural Product Research. 37(13). 2243–2247. 4 indexed citations
16.
17.
Li, Wenhan, Yongchun Song, Hao Zhang, et al.. (2017). Decreased Expression of Hsa_circ_00001649 in Gastric Cancer and Its Clinical Significance. Disease Markers. 2017. 1–6. 102 indexed citations
18.
Wang, Ting, Changxi Wang, Jinghua Wu, et al.. (2016). The Different T-cell Receptor Repertoires in Breast Cancer Tumors, Draining Lymph Nodes, and Adjacent Tissues. Cancer Immunology Research. 5(2). 148–156. 51 indexed citations
19.
Wang, Ting, Robert Grabski, Elizabeth Sztul, & Jesse Hay. (2014). p115 –SNARE Interactions: A Dynamic Cycle of p115 Binding Monomeric SNARE Motifs and Releasing Assembled Bundles. Traffic. 16(2). 148–171. 18 indexed citations
20.
Wang, Ting, et al.. (2002). Cladistic analysis of sequences of chloroplast rbcL gene and trnL-trnF intergenic spacer in Taxaceae and related taxa. 41(4). 70–74. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026